Kontakt
QR-Code für die aktuelle URL

Story Box-ID: 59270

Capsulution Pharma AG Volmerstr. 7b 12489 Berlin, Deutschland http://www.capsulution.com/
Ansprechpartner:in Dr. Sascha General +49 30 46817655
Logo der Firma Capsulution Pharma AG
Capsulution Pharma AG

Capsulution signs cooperation agreement with Schering and AcriTec

Berlin based company develops new products in the field of the nanoparticle based delivery of active substances.

(PresseBox) (Berlin, )
In March the Capsulution NanoScience AG, a Berlin based nanotechnology company that is specialised in the development of intelligent “packaging” systems for active substances has signed a cooperation agreement with Schering AG and Acri.Tec GmbH. The cooperation project is supported by the German Federal Ministry of Education and Research (BMBF). Goal of the cooperation is the development of advanced drug delivery systems designed for a more effective application of drugs.

Within the next three years, the companies will concentrate on special hydro-gels that on the one hand have the quality for best possible usage and transport and on the other hand are capable for the controlled release of embedded nanoparticles. These nanoparticles contain active substances and the release of them can take place via a controlled time frame. The combination of functional hytro-gels and embedded nanoparticles enables a targeted release of active substances, which reduces the dosage frequency of the application and increases the therapy safety.

Two different indications of pharmacotherapy are within the focus of the development cooperation. One application is the contraception and treatment of various gynaecological diseases. And the other application is the therapy of retinal removal. Both application areas have special demands for drug-delivery-systems, but pursue the similar approach to nano-functional hydro-gels (NanoGel). The challenge of the cooperation is to determine the exact specification of hydro-gel and nanoparticle characteristics and to establish appropriate in-vitro systems.

The cooperation processes all interdisciplinary aspects from the research of polymers, development of drug-delivery-systems, clinical developments up to the manufacture of products. In this context there are further German research partners included to the project such as the Fraunhofer Institute for Applied Polymer Research IAP, the University of Regensburg and the ITEMP of the medical department of the Aachen University of Technology.

About Acri.Tec:
Acri.Tec GmbH is a company that develops innovative products in the field of ophthalmic surgery. The label “made in Germany” stands for best quality with high international acceptance. The product range primary includes intraocular lenses (substitute lenses for eye cataract patients), as well as other implants, hygienic fluids, surgical diamond-knifes, tools and other innovative special products. In 2001 the Acri.Tec GmbH was awarded by the states of Berlin and Brandenburg with the special Innovation-Award.

Capsulution Pharma AG

Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company implements its worldwide-patented LBL Technology®. Based on their minute size, their functionality and their highly reproducible production process, the tunable capsules can be used in a multitude of different applications. Accordingly, the precision-sized capsules can be made to function in a manner suited to the intended application, and can be given biochemical, electrical, optical and magnetic properties tailored to the individual customer. In order to meet customers’ needs for complete product solutions, Capsulution designated EBARA Corp. as the preferred developer, manufacturer and distributor for automated LBL units. In 2005, the renowned growth consultants Frost & Sullivan awarded the year’s “Product Differentiation Innovation Award” in the global nanobiotechnology market to Capsulution NanoScience AG, Berlin. The company received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications.

Für die oben stehenden Stories, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Titel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Texte sowie der angehängten Bild-, Ton- und Informationsmaterialien. Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.
Wichtiger Hinweis:

Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die unn | UNITED NEWS NETWORK GmbH gestattet.

unn | UNITED NEWS NETWORK GmbH 2002–2024, Alle Rechte vorbehalten

Für die oben stehenden Stories, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Titel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Texte sowie der angehängten Bild-, Ton- und Informationsmaterialien. Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.